Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The variable clinical outcomes of Multiple Myeloma (MM) patients are incompletely defined by current prognostication tools. We examined the clinical utility of high-resolution telomere length analysis as a prognostic marker in MM. Cohort stratification, using a previously determined length threshold for telomere dysfunction, revealed that patients with short telomeres had a significantly shorter overall survival (P < 0·0001; HR = 3·4). Multivariate modelling using forward selection identified International Staging System (ISS) stage as the most important prognostic factor, followed by age and telomere length. Importantly, each ISS prognostic subset could be further risk-stratified according to telomere length, supporting the inclusion of this parameter as a refinement of the ISS.

Original publication

DOI

10.1111/bjh.14643

Type

Journal article

Journal

Br J Haematol

Publication Date

07/2017

Volume

178

Pages

94 - 98

Keywords

genome instability, multiple myeloma, prognosis, telomere, DNA, Neoplasm, Genomic Instability, Humans, Kaplan-Meier Estimate, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Neoplasm Staging, Prognosis, Telomere Shortening